HPGC Renmintongtai Pharmaceutical (SHSE:600829) Total Equity: ¥3,063 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600829 HPGC Renmintongtai Pharmaceutical Corp SHSE:600829
55 GF Score
Price ¥8.95
GF Value ¥7.84
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is HPGC Renmintongtai Pharmaceutical Total Equity?

HPGC Renmintongtai Pharmaceutical SHSE:600829 -0.67% 55 Total Equity is ¥3,063 Mil as of Mar. 2026. GuruFocus rates SHSE:600829 with a GF Score™ of 55/100 and a GF Value™ of ¥7.84 (Modestly Overvalued). The stock has 2 warning signs investors should review.

HPGC Renmintongtai Pharmaceutical's total equity for the quarter that ended in Mar. 2026 was ¥3,063 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

HPGC Renmintongtai Pharmaceutical Total Equity Historical Data

* Premium members only.

The historical data trend for HPGC Renmintongtai Pharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HPGC Renmintongtai Pharmaceutical Total Equity Chart

HPGC Renmintongtai Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,199.23 2,458.20 2,751.38 2,881.14 3,014.98

HPGC Renmintongtai Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,926.99 2,953.72 2,993.02 3,014.98 3,063.45
SHSE:600829
55GF Score
HPGC Renmintongtai Pharmaceutical Corp SHSE:600829
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HPGC Renmintongtai Pharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

HPGC Renmintongtai Pharmaceutical's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7174.877-4159.893
=3,015

HPGC Renmintongtai Pharmaceutical's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=7353.266-4289.818
=3,063

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ¥3,063 Mil mean?
HPGC Renmintongtai Pharmaceutical (SHSE:600829) has a Total Equity of ¥3,063 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for HPGC Renmintongtai Pharmaceutical and its competitors.
Is HPGC Renmintongtai Pharmaceutical's Total Equity too high?
HPGC Renmintongtai Pharmaceutical's current Total Equity is ¥3,063 Mil. Overall, HPGC Renmintongtai Pharmaceutical has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HPGC Renmintongtai Pharmaceutical's Total Equity compare to ZTS and UTHR?
HPGC Renmintongtai Pharmaceutical's Total Equity of ¥3,063 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for HPGC Renmintongtai Pharmaceutical and its competitors. HPGC Renmintongtai Pharmaceutical's current Total Equity is ¥3,063 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HPGC Renmintongtai Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, HPGC Renmintongtai Pharmaceutical (SHSE:600829) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.84, compared to a current price of ¥8.95 — trading 14.2% above its estimated fair value. The current Total Equity is ¥3,063 Mil. HPGC Renmintongtai Pharmaceutical's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For HPGC Renmintongtai Pharmaceutical (SHSE:600829), the current Total Equity is ¥3,063 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) Overvalued in 2026?

Based on GuruFocus' analysis, HPGC Renmintongtai Pharmaceutical stock appears to be overvalued. The current stock price of ¥8.95 is trading 14.2% above its estimated GF Value™ of ¥7.84. GuruFocus considers HPGC Renmintongtai Pharmaceutical to be Modestly Overvalued.

Key valuation signals for SHSE:600829:

  • Total Equity: ¥3,063 Mil
  • GF Value™: ¥7.84 vs. price of ¥8.95 (14.2% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600829 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HPGC Renmintongtai Pharmaceutical Business Description

Address No. 76 Hengshan Road, Nangang District, Heilongjiang Province, Harbin, CHN, 150076
HPGC Renmintongtai Pharmaceutical Corp, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co Ltd is engaged in the production and sale of pharmaceuticals products in China.
55GF Score

Get the complete analysis for SHSE:600829

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.95
Price
¥7.84
GF Value